|
市場調查報告書
製藥企業分析報告：Boehringer Ingelheim
Boehringer Ingelheim: Pipeline * Products * Performance * Potential
|
製藥企業分析報告：Boehringer Ingelheim 是由出版商Espicom Business Intelligence在2009年09月所出版的。
這份英文市場調查報告書包含Pages: 120 價格從美金1040起跳。
提供醫療儀器、藥品相關情報，獲得全球高度評價的英國市調公司 Espicom Business Intelligence，調查分析了製藥企業Boehringer Ingelheim後，出版了一本綜合報告書"Boehringer Ingelheim: Performance, Products, Pipeline and Potential"。
報告書內容包括：企業策略、產品組合、財務成績、2000年至2010年銷售資料等等，內容綱要摘記如下：
摘要
- 摘要
- 2005年財務成績
- 企業策略
- 產品、研發概要
- 結論
產品組合、研發
- 呼吸器官
- 心臟血管
- 免疫、發炎
- 泌尿器官
- 中樞神經
- 病毒
- 癌症
附錄
- 財務成績
- 主要合作
- 基礎建設
- 相關企業、合作夥伴
- 產品索引
Abstract
Pharmaceutical company intelligence reports from Espicom provide a full review
of the company' s activities together with five-year sales forecasts for its
key products. The company' s financial performance is covered in-depth, from
its latest results to a complete analysis of its latest full fiscal year and
an outlook for the future. A section on company strategy covers mergers,
acquisitions and divestitures, key agreements, products and R&D. An overview
of key products and R&D is followed by a comprehensive review of the company' s
product portfolio and research and development pipeline by therapeutic area.
In addition, supplementary appendices provide more in-depth information on
financials, agreements and corporate events.
Table of Contents
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company
strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
- Key product analysis and forecasting
- Respiratory
- Combivent (ipratropium bromide+albuterol)
- Spiriva (tiotropium bromide)
- Cardiovascular
- Aggrenox (dypyridamole+acetylsalicylic acid)
- Micardis (telmisartan)
- Pradaxa (dabigatran)
- Urology
- Flomax/Alna (tamsulosin)
- Central Nervous System
- Cymbalta/Xeristar (duloxetine)
- Sifrol/Mirapex/Mirapexin (pramipexole)
- Virology
- Aptivus (tipranavir)
- Viramune (nevirapine)
OPERATIONAL DATA
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key corporate events
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
|
